Key result
Interim PET/CT after two cycles of R-CHOP in DLBCL showed that only Deauville score 5 predicted inferior 5-year progression-free survival.
Why the study?
The study was conducted to assess the prognostic value of early FDG-PET/CT in diffuse large B-cell lymphoma treated with R-CHOP.
Does early FDG-PET/CT after two cycles of R-CHOP predict complete remission and survival outcomes in patients with DLBCL?
Cohort (n=189)
Blinded reporting
Yes
Does early FDG-PET/CT after two cycles of R-CHOP predict complete remission and survival outcomes in patients with DLBCL?
Early FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission, but only a Deauville score of 5 identifies patients with poor progression-free and overall survival.
Answers are grounded in this paper and cite their sources.
DS 5 on interim PET/CT identifies high-risk DLBCL; leaves open whether PET-guided intensification improves outcomes.
Summary The UK National Cancer Research Institute initiated a prospective study (UKCRN‐ID 1760) to assess the prognostic value of early fluorodeoxyglucose (FDG)‐positron emission tomography (PET)/computed tomography (CT) in diffuse large B‐cell lymphoma (DLBCL). In total, 189 patients with DLBCL treated with R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) had baseline and post‐cycle‐2 PET (PET2) within a quality assurance framework. Treatment decisions were based on CT; PET2 was archived for central blinded reporting after treatment completion. The association of PET2 response with end‐of‐treatment CT, progression‐free (PFS) and overall survival (OS) was explored. The end‐of‐treatment complete response rate on CT was 83·9%, 75·0%, 70·5%, 40·4% and 36·4% for Deauville score (DS) 1 ( n = 34), 2 ( n = 39), 3 ( n = 46), 4 ( n = 56) and 5 ( n = 14) ( P < 0·001); and 64·1% and 50·0% for the maximum standardised uptake value (∆SUV max ) of ≥66% ( n = 168) and <66% ( n = 21), respectively ( P = 0·25). After a median 5·4 years of follow‐up, the 5‐year PFS was 69·4%, 72·8%, 76·7%, 71·2% and 47·6% by DS 1–5 ( P = 0·01); and 72·6% and 57·1% by ∆SUV max of ≥66% and <66% ( P = 0·03), respectively. The association with DS remained in multivariable analyses, and was consistent for OS. Early complete metabolic response (DS 1–3) at interim PET/CT after two cycles of R‐CHOP in DLBCL was associated with a higher end‐of‐treatment complete and overall response rate; however, only DS‐5 patients had inferior PFS and OS.
No takes yet. Share an insight, caveat, or question.
Mikhaeel et al. (2020) conducted a cohort in Diffuse large B-cell lymphoma (DLBCL) (n=189). Early FDG-PET/CT (post-cycle-2) vs. Different Deauville scores (DS 1-5) was evaluated on End-of-treatment complete response rate on CT, progression-free survival, and overall survival (p=<0.001). Interim PET/CT after two cycles of R-CHOP in DLBCL showed that only Deauville score 5 predicted inferior 5-year progression-free survival.
Synapse has enriched 10 related papers. Consider them for comparative context: